Evaluation of adrenal function in patients with growth hormone deficiency and hypothalamic–pituitary disorders: comparison between insulin-induced hypoglycemia, low-dose ACTH, standard ACTH and CRH stimulation tests

M Maghnie, E Uga, F Temporini, N Di Iorgi, A Secco, C Tinelli1, A Papalia2, MR Casini3 and S Loche3

Department of Pediatrics, 1Department of Biometry – Scientific Direction, 2Servizio Analisi Clinico Cliniche, IRCCS Policlinico S. Matteo, University of Pavia, I-27100 Pavia, Italy and 3Pediatric Endocrine Service, Ospedale Regionale le Microcitemie, Cagliari, Italy

(Correspondence should be addressed to M Maghnie; Email: maghnie@smatteo.pv.it)

Abstract

Objectives: Patients with organic growth hormone deficiency (GHD) or with structural hypothalamic–pituitary abnormalities may have additional anterior pituitary hormone deficits, and are at risk of developing complete or partial corticotropin (ACTH) deficiency. Evaluation of the integrity of the hypothalamic–pituitary–adrenal axis (HPA) is essential in these patients because, although clinically asymptomatic, their HPA cannot appropriately react to stressful stimuli with potentially life-threatening consequences.

Design and methods: In this study we evaluated the integrity of the HPA in 24 patients (age 4.2 – 31 years at the time of the study) with an established diagnosis of GHD and compared the reliability of the insulin tolerance test (ITT), short synacthen test (SST), low-dose SST (LDSST), and corticotropin releasing hormone (CRH) test in the diagnosis of adrenal insufficiency.

Results: At a cortisol cut-off for a normal response of 550 nmol/l (20 μg/dl), the response to ITT was subnormal in 11 subjects, 6 with congenital and 5 with acquired GHD. Four patients had overt adrenal insufficiency, with morning cortisol concentrations ranging between 66.2 – 135.2 nmol/l (2.4 – 4.9 μg/dl) and typical clinical symptoms and laboratory findings. In all these patients, a subnormal cortisol response to ITT was confirmed by LDSST and by CRH tests. SST failed to identify one of the patients as adrenal insufficient. In the seven asymptomatic patients with a subnormal cortisol response to ITT, the diagnosis of adrenal insufficiency was confirmed in one by LDSST, in none by SST, and in five by CRH tests. The five patients with a normal cortisol response to ITT exhibited a normal response also after LDSST and SST. Only two of them had a normal response after a CRH test. In the seven patients with asymptomatic adrenal insufficiency mean morning cortisol concentration was significantly higher than in the patients with overt adrenal insufficiency. ITT was contraindicated in eight patients, and none of them had clinical symptoms of overt adrenal insufficiency. Four patients had a subnormal cortisol response to LDSST, SST, and CRH, and three exhibited a subnormal response to CRH but normal responses to LDSST and to SST.

Conclusion: We conclude that none of these tests can be considered completely reliable for establishing or excluding the presence of secondary or tertiary adrenal insufficiency. Consequently, clinical judgment remains one of the most important issues for deciding which patients need assessment or re–assessment of adrenal function.

European Journal of Endocrinology 152 735–741

Introduction

A substantial number of patients with isolated growth hormone deficiency (GHD) may have additional anterior pituitary hormone deficits (1–3). Patients with idiopathic GHD are at risk of developing complete or partial corticotropin (ACTH) deficiency. Lange et al. (4) have recently reported that 44% of adult subjects with childhood–onset GHD developed asymptomatic adrenal insufficiency. Walvoord et al. reported that all but one patient with GHD and additional ACTH deficiency had an ectopic posterior pituitary at magnetic resonance imaging (5). However, although clinically asymptomatic, the hypothalamic–pituitary–adrenal axis (HPA) of these patients cannot appropriately react to stressful stimuli, with potentially life–threatening consequences. Thus, evaluation of the integrity of the HPA is essential in patients with GHD.
Although the diagnosis of overt adrenal failure is generally straightforward, identification of those asymptomatic patients with subtle dysfunction of the HPA axis is still a diagnostic challenge. The HPA axis response to insulin hypoglycemia (ITT) is still considered the gold standard in the evaluation of suspected adrenal insufficiency, even though its validity has been recently questioned (6–8). Furthermore, ITT is contraindicated in infants, and in patients with cardiovascular disease or a history of seizures. Patients with multiple pituitary hormone deficiencies experienced severe hypoglycemia during ITT (9), and occasional deaths in children have been reported with the use of such tests (10). Therefore, alternative tests to evaluate the HPA have been proposed, such as glucagon, metyrapone, ACTH and corticotropin releasing hormone (CRH) testing (4, 6). Since the adrenal gland can respond to exogenous ACTH administration when there is a sufficient endogenous ACTH reserve, the short synacthen test (SST) has been introduced to test the HPA in patients with secondary adrenal insufficiency or after corticosteroid withdrawal (11). More recently, a low–dose (1 μg) SST (LDSST) has been proposed to be more sensitive in the evaluation of the integrity of the HPA (12–17). Results of CRH testing have been reported in some patients with adrenal insufficiency (18–20), and a good correlation was found between the responses to CRH and ITT.

This study was prospectively designed to test the integrity of the HPA axis in patients with an established diagnosis of GHD. Since ITT was contraindicated in many of our patients, we designed this study to compare the reliability of the ITT, SST, LDSST and CRH test in the diagnosis of adrenal insufficiency.

**Subjects and methods**

The study population comprised 24 patients (12 males and 12 females) with established childhood–onset GHD of congenital or acquired origin, diagnosed at a mean age of 9.6±6.0 years (range 2.0–20.0 years). The diagnosis of GHD was established on the basis of failure of growth hormone (GH) to increase >10 μg/l after two stimulation tests (insulin hypoglycaemia and arginine). In all patients, insulin-like growth factor-I (IGF-I) concentrations were lower than those of age-matched normal subjects. Nine patients had vasopressin deficiency, two had thyrotropin (TSH) deficiency (one after cranial irradiation), five had gonadotropin deficiency and one had hypergonadotropic hypogonadism (chemotherapy-induced). All patients were receiving appropriate hormonal replacement treatment for their hormonal deficits. Subjects with multiple pituitary hormone deficiencies (MPHD) were receiving conventional replacement therapy for pituitary deficits: l-thyroxine (150–250 mg intramuscularly every 2 or 3 weeks for males and transdermal 17 β-estradiol patches with medroxyprogesterone acetate (5–10 mg, days 12 to 21) for females), desmopressin acetate (DDAVP; two or three times daily, either intranasally or orally in cases with central diabetes insipidus) and recombinant human GH (0.025–0.030 mg/kg/week, given s.c. 6 to 7 times/week to pediatric-age patients and at a dose of between 0.5–1 mg/day to the others).

Magnetic resonance imaging (MRI) technique with the use of contrast medium as previously described (21) revealed congenital hypothalamic–pituitary abnormalities, such as anterior pituitary gland hypoplasia, pituitary stalk agenesis and posterior pituitary ectopia at the infundibular recess (n = 12) and acquired lesions, including idiopathic, likely ‘inflammatory’, pituitary stalk thickness (n = 5), Langherans cells histiocytosis (LCH)–dependent pituitary stalk thickness (n = 4), brain tumor (n = 1), pituitary hypoplasia as the result of head trauma and skull fracture (n = 1) and pituitary adenoma (n = 1). The diagnosis of idiopathic pituitary stalk thickness was based on MR findings of a large pituitary stalk (22) in the absence of other imaging or laboratory markers of specific diseases, including LCH, sarcoidosis, tuberculosis, germinomas or systemic disorders. Biopsy-proven LCH at the level of skin or bone lesions were obtained in all affected patients.

The main clinical findings of the patients are summarized in Table 1. The study was approved by the Department of Pediatrics Institutional Review Board and written informed consent was obtained from the patients and their patients.

**Study design**

The ITT (0.1 U/kg BW i.v. of human Actrapid insulin) was performed in 16 patients, since it was contraindicated in eight subjects. Plasma cortisol and glucose were measured at baseline and at time points 30, 60, 90, and 120 min after insulin administration. Results were accepted if blood glucose had dropped to levels below 2.2 nmol/l (<40 mg/dl) in association with glucopenic symptoms. Blood samples for cortisol and plasma glucose were drawn from an indwelling catheter inserted in an antecubital vein and measured at baseline and at time points 30, 60, 90, and 120 min after insulin administration.

The LDSST was performed in all patients. Blood samples for cortisol were measured at time points 0, 10, 20, 30 and 45 min after the injection of 1 μg tetra-cosactrin (Synacthen, Novartis Pharma S.A., Hünigue, France). A dilute solution was prepared by adding 250 μg to 50 ml 0.9% NaCl in a plastic infusion bag. Further dilution was performed by taking 0.2 ml of the solution and adding 0.8 ml NaCl. The resulting solution of 1 μg ACTH/ml was used immediately after preparation.
The SST (250 μg tetracosactrin; Synacthen) and the CRH tests (1 μg/kg human CRH, Ferring Arzneimittel GmbH, Wittland, Kiel, Germany) were performed i.v. in all patients. Blood samples for cortisol were taken at time points 0, 30, and 60 min after both tests. All tests were performed in the morning between 0800–0900 h after the patients had fasted overnight. The 4 tests were performed within 1 month on separate days after an interval of 7 days. The samples were centrifuged at 4°C, and the plasma was separated and stored at −20°C until assayed. A serum cortisol increase to at least 550 nmol/l (20 mg/dl) was the criterion for a functioning HPA (provided the blood glucose nadir was 2.2 nmol/l, 40 mg/dl during ITT).

In our laboratory, normal morning cortisol concentrations are 138–635 nmol/l (5–23 μg/dl), while the cut-off for a normal cortisol response is > 550 nmol/l (20 μg/dl) to ITT, SST, and LDSST and > 500 nmol/l (18 μg/dl) to CRH. These cut-off points have been established in 43 normal subjects after ITT, 28 after SST, 25 after LDSST and 20 after CRH. Data are given as the mean ± S.E.

### Assay procedures

Cortisol was measured by radioimmunoassay using commercial kits (Elecsys, Roche Diagnostics, Mannheim, Germany). The intra- and inter-assay coefficients of variations were 1.3, 1.3 and 1.1%, and 1.6, 1.5 and 1.6%, respectively at cortisols level of 207.8, 560.0 and 1269.1 nmol/l (7.53, 20.3 and 46 μg/dl). Serum glucose was routinely determined with the glucose oxidase method.

### Results

All 16 patients who underwent the ITT had dropped blood glucose to levels below 2.2 nmol/l (<40 mg/dl) and exhibited one or more clinical symptoms and signs of hypoglycemia, including tachycardia, a sense of hunger, sweating or mental confusion. With a cut-off for a normal response of 550 nmol/l (20 mg/dl), the cortisol peak after ITT was subnormal in 11 subjects, six with congenital and five with acquired GHD (Fig. 1). Four patients (patients 7, 12, 13 and 15) had overt adrenal insufficiency, with morning cortisol concentrations ranging between 66.2–135.2 nmol/l (2.4–4.9 mg/dl) and typical clinical symptoms and laboratory findings (Table 2). In all these patients, a subnormal cortisol response to ITT was confirmed by LDSST and by CRH test. SST failed to identify one of the patients as adrenal insufficient (Fig. 1).

### Table 1

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age/diagnosis (years)</th>
<th>Age/study (years)</th>
<th>Etiology</th>
<th>Hormone deficits</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>M</td>
<td>4.2</td>
<td>4.2</td>
<td>EPP, APH, PSA</td>
<td>GH</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>3.2</td>
<td>10.8</td>
<td>EPP, APH, PSA</td>
<td>GH / FSH / LH</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>2.0</td>
<td>16.6</td>
<td>EPP, APH, PSA</td>
<td>GH / FSH / LH</td>
</tr>
<tr>
<td>4</td>
<td>F</td>
<td>6.4</td>
<td>17.2</td>
<td>EPP, APH, PSA</td>
<td>GH</td>
</tr>
<tr>
<td>5</td>
<td>M</td>
<td>8.5</td>
<td>17.6</td>
<td>EPP, APH, PSA</td>
<td>GH / FSH / LH</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>2.0</td>
<td>21.2</td>
<td>EPP, APH, PSA</td>
<td>GH / FSH / LH</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>14.0</td>
<td>21.9</td>
<td>EPP, APH, PSA</td>
<td>GH</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>6.6</td>
<td>22.2</td>
<td>EPP, APH, PSA</td>
<td>GH / FSH / LH</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>4.0</td>
<td>24.1</td>
<td>EPP, APH, PSA</td>
<td>GH</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>9.0</td>
<td></td>
<td>EPP, APH, PSA</td>
<td>GH / FSH / LH</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>11.6</td>
<td>31.0</td>
<td>IPST</td>
<td>GH / AVP</td>
</tr>
<tr>
<td>12</td>
<td>M</td>
<td>8.7</td>
<td>13.7</td>
<td>IPST</td>
<td>GH / AVP</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>13.2</td>
<td>13.9</td>
<td>IPST</td>
<td>GH / FSH / LH / AVP</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>6.3</td>
<td>14.8</td>
<td>IPST</td>
<td>GH / AVP</td>
</tr>
<tr>
<td>15</td>
<td>M</td>
<td>12.8</td>
<td>16.8</td>
<td>IPST</td>
<td>GH / AVP</td>
</tr>
<tr>
<td>16</td>
<td>M</td>
<td>9.8</td>
<td>17.0</td>
<td>IPST</td>
<td>GH / AVP</td>
</tr>
<tr>
<td>17</td>
<td>F</td>
<td>9.7</td>
<td>18.3</td>
<td>IPST</td>
<td>GH / FSH / LH / AVP</td>
</tr>
<tr>
<td>18</td>
<td>F</td>
<td>11.0</td>
<td>11.6</td>
<td>LCH</td>
<td>GH</td>
</tr>
<tr>
<td>19</td>
<td>F</td>
<td>9.5</td>
<td>16.9</td>
<td>LCH</td>
<td>GH / AVP / hypogonadism a</td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>20.0</td>
<td>25.8</td>
<td>LCH</td>
<td>GH / AVP / TSH</td>
</tr>
<tr>
<td>21</td>
<td>M</td>
<td>8.2</td>
<td>25.8</td>
<td>LCH</td>
<td>GH / FSH / LH / AVP</td>
</tr>
<tr>
<td>22</td>
<td>F</td>
<td>5.6</td>
<td>15.6</td>
<td>LCH</td>
<td>GH / hypothyroidism b</td>
</tr>
<tr>
<td>23</td>
<td>F</td>
<td>18.0</td>
<td>18.3</td>
<td>head trauma</td>
<td>GH / FSH / LH</td>
</tr>
<tr>
<td>24</td>
<td>F</td>
<td>18.2</td>
<td>21.5</td>
<td>adenoma</td>
<td>GH / FSH / LH</td>
</tr>
</tbody>
</table>

EPP, ectopic posterior pituitary; APH, anterior pituitary hypoplasia; PSA, pituitary stalk agenesis; IPST, idiopathic pituitary stalk thickness; LCH, Langerhans-cell histiocytosis; adenoma, pituitary non-secreting adenoma.

a Hypergonadotrophic hypogonadism.
b Acquired hypothyroidism.
The five patients with a normal cortisol response to ITT (patients 2, 9, 17, 18, and 21) exhibited a normal response also after LDSST and SST. Only two of them had a normal response after CRH (patients 9 and 18) (Fig. 1). Mean baseline cortisol concentrations were significantly lower in the four patients with overt adrenal insufficiency than in the five patients with a normal response to ITT ($P = 0.03$ by Mann–Whitney U test). In the seven patients with asymptomatic adrenal insufficiency, mean morning cortisol concentration was significantly higher than in the patients with overt adrenal insufficiency (234.5 ± 35.9 vs 104.8 ± 33.1 nmol/l (8.5 ± 1.3 vs. 3.8 ± 1.2 μg/dl) $P = 0.0001$ by Mann–Whitney U test). None of the patients in whom ITT was contraindicated (patients 4, 5, 8, 19, 20, 22, 23, and 24) had clinical symptoms of overt adrenal insufficiency. One of these patients (patient 5) had a subnormal cortisol response to LDSST, SST, and CRH. Three more patients (patients 8, 22, 24) exhibited a subnormal response to CRH but normal responses to LDSST and to SST (Fig. 2).

**Discussion**

The clinical spectrum of adrenal insufficiency ranges from the clinically manifest adrenal crisis to subtle dysfunctions in asymptomatic patients. Patients with slight dysfunctions are at risk of developing acute adrenal crisis since their HPA cannot appropriately react to stress. Thus, identification of patients with subtle abnormality of the HPA is mandatory for avoiding this life-threatening event in stressful conditions. Patients with GHD are particularly at risk of developing adrenal insufficiency (1–4), and those with multiple pituitary hormone deficiency may have a lower secretory cortisol capacity than healthy subjects (23), suggesting that careful monitoring of HPA in these patients is recommended. The cortisol

<table>
<thead>
<tr>
<th>Patient</th>
<th>Morning cortisol (nmol/l (μg/dl))</th>
<th>Fatigue</th>
<th>Orthostatic hypotension</th>
<th>Gastrointestinal symptoms</th>
<th>Pallor</th>
<th>Depression anorexia</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>215.2 (7.8)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2</td>
<td>251.1 (9.1)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>179.3 (6.5)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>350.4 (12.7)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>240.0 (8.7)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>245.6 (8.9)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>7</td>
<td>135.2 (4.9)</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>8</td>
<td>270.4 (9.8)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>9</td>
<td>240.0 (8.7)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>10</td>
<td>212.4 (7.7)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>11</td>
<td>259.3 (9.4)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>12</td>
<td>129.7 (4.7)</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>13</td>
<td>93.8 (3.4)</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>14</td>
<td>284.2 (10.3)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>15</td>
<td>66.2 (2.4)</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>16</td>
<td>248.3 (9.0)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>17</td>
<td>237.3 (8.6)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>18</td>
<td>226.2 (8.2)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>19</td>
<td>300.7 (10.9)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>20</td>
<td>435.9 (15.8)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>21</td>
<td>303.5 (11.0)</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>22</td>
<td>256.6 (9.3)</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>23</td>
<td>206.9 (7.5)</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>24</td>
<td>179.3 (6.5)</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*Asymptomatic patients with maximum cortisol response after ITT test < 20 μg/dl.

+ Patients with maximum cortisol response after ITT test > 20 μg/dl.

- Patients with adrenal insufficiency. Patients 4, 5, 8, 19, 20, 22, 23, and 24 had no ITT.
response to ITT has been validated against the response to surgical stress and is considered the refer-
ence test to evaluate the integrity of the HPA (6–8). Reportedly (6–8), a cortisol response to ITT of
500–550 nmol/l (18–20 µg/dl) reflects normal func-
tioning of the axis. However, the ITT is contraindi-
cated in infants, and in patients with cardiovascular
disease or a history of seizures. For this reason vari-
ous authors have proposed alternatives to the ITT,
including SST, LDSST and CRH tests.

Among the subjects in this study who underwent
ITT, the test identified as adrenal insufficient four
patients with typical clinical symptoms. The diagnosis
was confirmed in all four patients by both LDSST and
the CRH test, while the cortisol response to SST was
normal in one. These patients also had subnormal
baseline morning cortisol concentrations, although all
available data indicate that a low morning cortisol con-
centration alone is not a reliable predictor of overt adre-
nal insufficiency (24, 25). A subnormal cortisol
response to ITT was also found in seven asymptomatic
patients, which was not confirmed by SST. The diagno-
sis was also not confirmed in one and five patients,
respectively, by LDSST and CRH. Therefore, in this
subset of patients, the response to CRH correctly identi-
ified all but two patients with adrenal insufficiency,
while both LDSST and SST were far less accurate. In
other words, the LDSST and the SST yielded normal
responses in patients with subtle dysfunctions of the
HPA detected by ITT. All eight patients in whom ITT
was contraindicated were apparently asymptomatic.
One of them had a subnormal cortisol response to
SST, LDSST and CRH, while three other patients
showed discordant responses to the three tests. Based
on the results of the group of patients who underwent
ITT, subtle adrenal insufficiency could not be excluded
in these subjects.

Our results contrast with those reported by other
investigators. Weintrob et al. (12) found that in patients
with idiopathic multiple pituitary hormone deficits,
both SST and LDSST were equivalent to ITT in
detecting HPA insufficiency. One of the possible expla-
nations for these contrasting findings may be the fact
that in their study all patients may have had clinical
adrenal insufficiency, as indicated by their low baseline
cortisol concentrations (80±24 nmol/l), close to the
values of our four patients with overt adrenal insuffi-
ciency. Abdu et al. (16) reported that at cortisol cut-
off levels of 500 or 600 nmol/l, all patients who failed
the ITT also failed the LDSST. They suggested that at
a cortisol cut-off of 600 nmol/l the LDSST is 100% sen-
sitive without any falsely reassuring results. Other
authors have reported a good correlation between the
cortisol response to ITT and to LDSST (14, 15, 18) or
SST. However, most of these studies have been per-
formed in adult subjects. In a study involving thirty-
two patients aged 2–19 years with clinical symptoms
suggestive of adrenal insufficiency, Agwu et al. (15)
found that the LDSST revealed a mild degree of adrenal
insufficiency not detected by the SST; similar findings
have been reported in another study by Gonçalves et al.
(23). In their studies, however, none of the patients
were tested with the ITT. Ambrosi et al. (14) suggested
that LDSST is a useful tool for the initial assessment of
HPA function in patients with hypothalamic–pituitary
disease. However, a 100% concordance with the ITT
was found only at a cut-off of 750 nmol/l, whereas
using a cut-off of 500 nmol/l, the results of ITT and
LDSST were concordant in 88% of patients. Thus, it
seems that the cortisol response to LDSST consistently
 correlates with that of the ITT only when the patients
have overt adrenal insufficiency, or at cut-off values
higher than 500–550 nmol/l. On the other hand, it
must be kept in mind that in occasional cases even
the ITT may fail to identify patients with clinically evi-
dent cortisol deficiency (16, 26).

Although the results of CRH testing have been
reported to correlate with those of ITT in patients
with glucocorticoid-induced corticotropin deficiency
(18, 20, 27), the CRH test has not generally been
regarded as a useful tool in the clinical setting (20,
27). Moreover, the variability of cortisol response to
CRH has been possibly attributed to compounding fac-
tors, such as preceding corticosteroid therapy or con-
comitant desmopressin treatment (28). In our study, the
cortisol response to CRH was not always correlated
with that of the ITT, with the exception of the four
patients with overt adrenal insufficiency. Similar to pre-
vious findings, in our normal subjects the cortisol
response to CRH was highly variable. Thus, the
lowest cortisol value was chosen as the limit for
normal response. Even with these limitations, it
provided better results than the SSL and LDSST and it
may be considered useful in patients in whom ITT
is contraindicated. It must also be pointed out that
while the cost of SST, LDSST and ITT is on average
comparable to that of routine tests in an endocrine

setting, the CRH test is still burdened by the cost of the peptide.

In conclusion, none of the tests employed in this study can be considered completely reliable for establishing or excluding the presence of secondary or tertiary adrenal insufficiency, although ITT seems to be the most sensitive for detecting sub clinical or partial ACTH deficiency. Based on the above considerations, our patients in whom ITT was contraindicated cannot be safely considered to have an intact HPA. Therefore, we suggest that patients with isolated GHD or combined pituitary hormone deficiency who are at risk of developing adrenal insufficiency but who cannot undergo ITT be carefully monitored clinically and biochemically. MRI might be of help in identifying those patients with GHD at higher risk of developing other pituitary hormone deficits. In fact, patients with non-identified pituitary stalks have been found to be at a risk of developing associated hormonal deficits 7 times greater than those with an identified pituitary stalk (21). Our study points out that patients with structural hypothalamic–pituitary abnormalities may develop subtle to complete ACTH deficiency and that these patients should be alerted of the potential risk of acute adrenal insufficiency in cases of stressful events.

References


Received 9 December 2004
Accepted 11 February 2005